Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Sri Harsha Tella & Marc S Rendell. (2015) DPP-4 inhibitors: focus on safety. Expert Opinion on Drug Safety 14:1, pages 127-140.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Thomas Forst & Peter Bramlage. (2014)
Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opinion on Pharmacotherapy 15:9, pages 1299-1313.
Read now
Read now
Stephanie A Stein, Elizabeth M Lamos & Stephen N Davis. (2014)
Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 599-608.
Read now
Read now
Ibrahim Gueler, Susanne Mueller, Matthias Helmschrott, Christian U Oeing, Christian Erbel, Lutz Frankenstein, Christian Gleißner, Arjang Ruhparwar, Philipp Ehlermann, Thomas J Dengler, Hugo A Katus & Andreas O Doesch. (2013) Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Design, Development and Therapy 7, pages 297-303.
Read now
Read now
Ling-Ling Dai, Lan Fan, Hui-Zi Wu, Zhi-Rong Tan, Yao Chen, Xiang-Dong Peng, Min-Xue Shen, Guo-Ping Yang & Hong-Hao Zhou. (2013) Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects. Xenobiotica 43:10, pages 862-867.
Read now
Read now
Matilda Florentin & Moses S Elisaf. (2012) Simvastatin interactions with other drugs. Expert Opinion on Drug Safety 11:3, pages 439-444.
Read now
Read now
Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino & Jennifer B Green. (2010) Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2, pages 7-19.
Read now
Read now
S. Halimi, D. Raccah, A. Schweizer & S. Dejager. (2010) Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Current Medical Research and Opinion 26:7, pages 1647-1656.
Read now
Read now
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya & Anthony H. Barnett. (2009) DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine 121:6, pages 70-100.
Read now
Read now
Moulinath Banerjee, Naveed Younis & Handrean Soran. (2009) Vildagliptin in clinical practice: a review of literature. Expert Opinion on Pharmacotherapy 10:16, pages 2745-2757.
Read now
Read now
Andreas Holstein & Winfried Beil. (2009) Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opinion on Drug Metabolism & Toxicology 5:3, pages 225-241.
Read now
Read now
Serge Halimi, Anja Schweizer, Biljana Minic, James Foley & Sylvie Dejager. (2008) Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
. Vascular Health and Risk Management 4:3, pages 481-492.
Read now
Read now
Articles from other publishers (24)
Kunika Saini, Smriti Sharma & Yousuf Khan. (2023) DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Aikaterini Saiti, Alexandros Giannopoulos-Dimitriou, Ioannis Kazakos, Eleftheria Galatou & Ioannis S. Vizirianakis. (2023) Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. Future Pharmacology 3:1, pages 329-363.
Crossref
Crossref
Donald J. AbrahamAnn E. Weber & Nancy A. Thornberry. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
48
.
Chin-Ying Ray, Victor Chien-Chia Wu, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Chang-Fu Kuo & Shang-Hung Chang. (2021) Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors. Frontiers in Pharmacology 12.
Crossref
Crossref
Beena Kumari & Aparna Khansili. (2020) Analytical Method Development and Validation of UV-visible
Spectrophotometric Method for the Estimation of Vildagliptin in Gastric
Medium. Drug Research 70:09, pages 417-423.
Crossref
Crossref
Lee M. Tatham, Neill J. Liptrott, Steve P. Rannard & Andrew Owen. (2019) Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?. Molecules 24:15, pages 2685.
Crossref
Crossref
Naina Mohamed Pakkir Maideen. (2019) Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World Journal of Meta-Analysis 7:4, pages 156-161.
Crossref
Crossref
Aimei Liu, Qinghua Wu, Jingchao Guo, Irma Ares, José-Luis Rodríguez, María-Rosa Martínez-Larrañaga, Zonghui Yuan, Arturo Anadón, Xu Wang & María-Aránzazu Martínez. (2019) Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacology & Therapeutics 195, pages 54-84.
Crossref
Crossref
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
Christina L. Aquilante, Michael F. Wempe, Maha S. Sidhom, Lisa A. Kosmiski & Julie A. Predhomme. (2013) Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. European Journal of Clinical Pharmacology 69:7, pages 1401-1409.
Crossref
Crossref
A L Vertkin, A Iu Magomedova, V B Mychka, Iu V Prokhorova & A V Nosova. (2012) The efficacy of application of vildagliptin in the patints presenting with co-morbid pathology. Problems of Endocrinology 58:3, pages 41-45.
Crossref
Crossref
Yan-Ling He. (2012) Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin. Clinical Pharmacokinetics 51:3, pages 147-162.
Crossref
Crossref
Patrizia Gazzerro, Maria Chiara Proto, Giuseppina Gangemi, Anna Maria Malfitano, Elena Ciaglia, Simona Pisanti, Antonietta Santoro, Chiara Laezza & Maurizio Bifulco. (2012) Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. Pharmacological Reviews 64:1, pages 102-146.
Crossref
Crossref
George P Samraj. (2011) Vildagliptin for the treatment of diabetes. Therapy 8:6, pages 703-719.
Crossref
Crossref
Joshua J. Neumiller. (2011) Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment. Clinical Therapeutics 33:5, pages 528-576.
Crossref
Crossref
C. F. Deacon. (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism 13:1, pages 7-18.
Crossref
Crossref
Gillian M. Keating. (2010) Vildagliptin. Drugs 70:16, pages 2089-2112.
Crossref
Crossref
André J. Scheen. (2010) Dipeptidylpeptitase-4 Inhibitors (Gliptins). Clinical Pharmacokinetics 49:9, pages 573-588.
Crossref
Crossref
Joshua J Neumiller, Lindy Wood & R. Keith Campbell. (2010) Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Pharmacotherapy 30:5, pages 463-484.
Crossref
Crossref
Abd A. Tahrani, Milan K. Piya, Amy Kennedy & Anthony H. Barnett. (2010) Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacology & Therapeutics 125:2, pages 328-361.
Crossref
Crossref
Donald J. AbrahamAnn E. Weber & Nancy A. Thornberry. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
39
76
.
Harunobu Ito, Teruaki Wajima, Masayuki Yamaguchi, Nobuyuki Mimori & Kaneo Sekiguchi. (2010) Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin. Folia Pharmacologica Japonica 136:5, pages 299-308.
Crossref
Crossref
C. Mathieu. (2009) The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes, Obesity and Metabolism 11, pages 9-17.
Crossref
Crossref